2 results match your criteria: ""METAXA" Memorial Piraeus Cancer Hospital[Affiliation]"
Genetic Predisposition to Male Breast Cancer: A Case Series.
Anticancer Res
December 2022
Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Greece.
Article Synopsis
- * Researchers analyzed genetic data from 100 Greek men diagnosed with MBC between 1995-2015, examining BRCA1, BRCA2, and 43 other cancer-related genes.
- * They found pathogenic variants in 13 patients, confirming BRCA2 as the primary genetic risk factor for MBC, while other genes had minimal involvement, complicating the assessment of their collective impact.
Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.
Support Care Cancer
August 2022
Department of Medical Oncology, "METAXA" Memorial Piraeus Cancer Hospital, Mpotasi 51, 185 37, Piraeus, Greece.
Background: Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment. Simultaneously, surgery is an additional risk factor.
Methods: The Metaxas's Hospital THromboprophylaxis program in Oncological & Surgical Patients (MeTHOS) is a prospective, phase IV, observational, non-interventional cohort study, aiming to record the thromboprophylaxis practice patterns in high-risk active cancer patients undergoing surgical and/or chemotherapy treatment.